NCT02142738View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

PHASE3CompletedINTERVENTIONAL
Enrollment

305

Participants

Timeline

Start Date

August 25, 2014

Primary Completion Date

May 9, 2016

Study Completion Date

May 27, 2021

Conditions
Non-Small Cell Lung Carcinoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab IV solution

DRUG

Paclitaxel

Paclitaxel IV solution

DRUG

Carboplatin

Carboplatin IV solution

DRUG

Pemetrexed

Pemetrexed Lyophilized Powder for Infusion

DRUG

Cisplatin

Cisplatin IV solution

DRUG

Gemcitabine

Gemcitabine Lyophilized Powder for Infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02142738 - Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | Biotech Hunter | Biotech Hunter